Vertex/CRISPR Are First To US FDA With A CRISPR Gene-Editing Therapy For Sickle Cell Disease
Executive Summary
The companies completed a rolling BLA filing for exagamglogene autotemcel (exa-cel) for sickle cell disease and beta thalassemia, a decade after the discovery of CRISPR.
You may also be interested in...
Bluebird Files Sickle Cell Gene Therapy, Just Weeks Behind Vertex
The company is seeking a priority review from the US Food and Drug Administration.
ICER Says Gene Therapies For Sickle Cell Likely To Improve Lives, But Points To Uncertainties
The drug pricing watchdog said improvement to patients’ quality and length of life from lovo-cel and exa-cel were likely, but noted ongoing uncertainty around durability and toxicity concerns.
Investors Take Flight After Bluebird Bio’s Sickle Cell Delay
Bluebird’s first two gene therapies are on the market, but a new delay to its biggest hope, the sickle cell disease candidate lovo-cell, has spooked investors.